我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
10 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2006
进行中（未招募）
100.0%
暂无批准数据
• Kronos Bio discontinued istisociclib (KB-0742) development after safety concerns arose in a Phase I/II trial for platinum-resistant high-grade serous ovarian cancer. • The trial revealed neurological adverse events in five of seven patients, leading to treatment discontinuation or dosage reduction in some participants. • Facing financial pressures, Kronos Bio is exploring strategic alternatives, including acquisition or merger, to maximize stockholder value and preserve cash. • The company is also seeking partnerships for preclinical assets KB-9558 and KB-7898, while focusing on IND application for multiple myeloma and autoimmune disorders.
